Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy

Objectives: to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2). Methods. 135 patients with breast cancer were randomly assigned at a ratio of 1:1:1 to rec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: P V Krivorotko, O N Burdaeva, M N Nechaeva, M A Frolova, M V Kopp, A A Abrosimova, R A Ivanov
Formato: Artigo
Idioma:Russo
Publicado em: IP Habib O.N. 2015-06-01
coleção:Современная онкология
Assuntos:
breast cancer
chemotherapy
neutropenia
filgrastim
empegfilgrastim
extimia®
Acesso em linha:https://modernonco.orscience.ru/1815-1434/article/view/27010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados